Actively Recruiting
The Effect of Laparoscopic Splenectomy on Liver Reserve Function for Cirrhosis Patients
Led by Northern Jiangsu People's Hospital · Updated on 2025-05-30
20
Participants Needed
1
Research Sites
N/A
Total Duration
On this page
AI-Summary
What this Trial Is About
This research aims to evaluate the improvement of liver reserve function indicators in patients with liver cirrhosis after they undergo laparoscopic splenectomy. The goal is to understand whether this surgical treatment can help enhance liver function after surgery and improve the overall outlook for these patients. The study includes patients diagnosed with cirrhosis and splenomegaly with related blood cell count issues. Patients will receive laparoscopic splenectomy performed by the same surgical team, followed by standardized nursing care. After surgery, all patients will get a consistent treatment plan including medications and other therapies. Liver reserve function will be monitored before surgery and at 3, 6, 12, and 24 months afterward, measuring various blood and liver function indicators such as TBIL, DBIL, ALB, ALT, INR, PT, Child-Pugh score, ascites, prealbumin, and specific liver function tests like ICG-K, ICG-R15, and ICG-T/2. Participants will provide general health information and undergo assessments at several time points after surgery. The research team will conduct blood tests and liver function evaluations to track changes over two years. The main measures are liver reserve function levels at 3, 6, 12, and 24 months after surgery. This study is sponsored by Northern Jiangsu People's Hospital and involves ongoing follow-up to monitor patient progress and liver function.
CONDITIONS
Brief Title
The Effect of Laparoscopic Splenectomy on Liver Reserve Function for Cirrhosis Patients
Who Can Participate
Eligibility Criteria
You may qualify if you...
- A clinical, radiological or histologic diagnosis of cirrhosis of any etiology
- Splenomegaly with secondary hypersplenism, Platelet count < 50*10^9/L
- Informed consent to participate in the study
You will not qualify if you...
- Hepatocellular carcinoma or any other malignancy
- Child-Pugh grade C
- Recent peptic ulcer disease
- History of Hemorrhagic stroke
- Pregnancy
- Uncontrolled Hypertension
- Bleeding portal hypertension
- Human immunodeficiency virus (HIV) infection
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Your Study Journey
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - Up to discharge after surgery
Participants undergo laparoscopic splenectomy performed by the same surgical team, followed by post-operative nursing care.
1 surgical procedure and immediate post-operative care visits
Duration - Up to 24 months after surgery
Participants receive a unified treatment plan including medication and other treatments after surgery.
Follow-up visits at 3, 6, 12, and 24 months post-surgery
Trial Site Locations
Total: 1 location
1
Clinical Medical College of Yangzhou University
Yangzhou, Jiangsu, China, 225001
Actively Recruiting
Research Team
G
Guo-Qing Jiang, MD
D
Dou-Sheng Bai, MD
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here